Srinivas Akkaraju - 18 Dec 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Signature
/s/ Srinivas Akkaraju
Issuer symbol
KLRS
Transactions as of
18 Dec 2025
Net transactions value
+$5,000,006
Form type
4
Filing time
17 Feb 2026, 20:15:32 UTC
Previous filing
09 Dec 2025
Next filing
22 Dec 2025

Reporting Owners (5)

Name Relationship Address Signature Signature date CIK
AKKARAJU SRINIVAS Director, 10%+ Owner C/O SAMSARA BIOCAPITAL, LLC, 628 MIDDLEFIELD ROAD, PALO ALTO /s/ Srinivas Akkaraju 17 Feb 2026 0001253170
Samsara BioCapital, L.P. 10%+ Owner C/O SAMSARA BIOCAPITAL, LLC, 628 MIDDLEFIELD ROAD, PALO ALTO Samsara BioCapital, L.P., By: Samsara BioCapital GP, LLC, its General Partner, By /s/ Srinivas Akkaraju, Managing Member 17 Feb 2026 0001699737
Samsara BioCapital GP, LLC 10%+ Owner C/O SAMSARA BIOCAPITAL, LLC, 628 MIDDLEFIELD ROAD, PALO ALTO Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member 17 Feb 2026 0001888829
Samsara Opportunity Fund, L.P. 10%+ Owner C/O SAMSARA BIOCAPITAL, LLC, 628 MIDDLEFIELD ROAD, PALO ALTO Samsara Opportunity Fund, L.P., By Samsara Opportunity Fund GP, LLC, its General Partner, By /s/ Srinivas Akkaraju, Managing Member 17 Feb 2026 0002086193
Samsara Opportunity Fund GP, LLC 10%+ Owner C/O SAMSARA BIOCAPITAL, LLC, 628 MIDDLEFIELD ROAD, PALO ALTO Samsara Opportunity Fund GP, LLC, By /s/ Srinivas Akkaraju, Managing Member 17 Feb 2026 0002086456

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KLRS Common Stock Purchase $5,000,006 +479,847 +32% $10.42 1,979,847 18 Dec 2025 By Samsara Opportunity Fund, L.P. F1, F2, F3
holding KLRS Common Stock 10,968,234 18 Dec 2025 By Samsara BioCapital, L.P. F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.
F2 Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby.
F3 Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
F4 The shares held by Samsara LP reflects the disposition of 479,847 shares, to Samsara Opportunity Fund as described in footnote (1), in which the Reporting Person had no pecuniary interest. The transfer of such shares by Samsara LP did not involve a change in the Reporting Person's beneficial ownership of such shares and, accordingly, was exempt from reporting under Section 16.
F5 Shares held by Samsara LP. The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.